<DOC>
	<DOCNO>NCT00462215</DOCNO>
	<brief_summary>The objective study assess immune response well safety tolerability H5N1 influenza vaccine adult elderly population . Further , study assess need booster vaccination whether 6-month booster 12-month booster appropriate . An independent data safety monitor board review evaluate safety data obtain study ongoing basis .</brief_summary>
	<brief_title>Phase 3 Immunogenicity Safety Study Inactivated H5N1 Influenza Vaccine ( Whole Virion , Vero Cell Derived )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>Male female subject eligible participation study : Are 18 59 year age day screen ( Stratum A ) , Are 60 year age old day screening ( Stratum B ) , Have understand study , agree provision , give write informed consent prior study entry , Are clinically healthy ( physical condition physician would reservations vaccinate influenza vaccine outside scope clinical study ) , Agree keep daily record symptom , If female capable bearing child negative urine pregnancy test result study entry agree employ adequate birth control measure duration study . Subjects exclude participation study : Have history exposure H5N1 virus history vaccination H5N1 influenza vaccine , Are high risk contract H5N1 influenza infection ( e.g . poultry worker ) , Suffer history significant cardiovascular , pulmonary , neurological , hepatic , rheumatic , autoimmune , hematological , metabolic renal disorder , Are unable lead independent life result either physical mental handicap , Suffer kind immunodeficiency , Suffer disease undergo treatment within 30 day prior study entry currently undergoing form treatment expect influence immune response . Such treatment include , limited , systemic high dose inhale ( &gt; 800Âµg/day beclomethasone dipropionate equivalent ) corticosteroid , radiation treatment immunosuppressive cytotoxic drug , Have history severe allergic reaction anaphylaxis , Have rash , dermatologic condition tattoo may interfere injection site reaction rating , Have receive blood transfusion immunoglobulin within 90 day study entry , Have donate blood plasma within 30 day study entry , Have receive live vaccine within 4 week inactivate vaccine within 2 week prior vaccination study , Have functional surgical asplenia , Have know suspect problem alcohol drug abuse , Were administer investigational drug within six week prior study entry concurrently participate clinical study include administration investigational product , Are member team conduct study dependent relationship study investigator . Dependent relationship include close relative ( i.e. , child , partner/spouse , sibling , parent ) well employee investigator , If female , pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>